Literature DB >> 2414754

Permanent cardiac pacing after open heart surgery: congenital heart disease.

B S Goldman, W G Williams, T Hill, P S Hesslein, P R McLaughlin, G A Trusler, R J Baird.   

Abstract

A retrospective review of 6,004 patients who underwent open repair of congenital heart defects revealed that 132 patients (2.2%) required permanent cardiac pacing postoperatively. The indications for pacing were early atrioventricular (AV) block in 55%, late onset AV block in 31%, and sick sinus syndrome in 14%. A ventricular septal defect (VSD) was the most common congenital anomaly present alone or in association with other lesions in 67% of the patients. Atrial surgery accounted for 21% of the patients requiring pacing. Ten-year patient survival was found to be 66% (+/- 6%). Thirty-five percent of the deaths were sudden and unexpected, presumably due to an arrhythmia. Reoperation for pacing system failure has occurred too frequently (12% per year). The most common causes for reoperation were battery failure (44%) and exit block (25%).

Entities:  

Mesh:

Year:  1985        PMID: 2414754     DOI: 10.1111/j.1540-8159.1985.tb05885.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  2 in total

1.  Bradyarrhythmias in Repaired Atrioventricular Septal Defects: Single-Center Experience Based on 34 Years of Follow-Up of 522 Patients.

Authors:  Corrado Di Mambro; Camilla Calvieri; Massimo Stefano Silvetti; Ilaria Tamburri; Salvatore Giannico; Anwar Baban; Sonia Albanese; Gianluca Brancaccio; Adriano Carotti; Fiore Salvatore Iorio; Fabrizio Drago
Journal:  Pediatr Cardiol       Date:  2018-06-13       Impact factor: 1.655

2.  Bradyarrhythmia development and permanent pacemaker implantation after cardiac surgery.

Authors:  Ceyhan Turkkan; Damirbek Osmanov; Ersin Yildirim; Kazim Serhan Ozcan; Servet Altay; Hakan Hasdemir; Ahmet Taha Alper; Nazmiye Ozbilgin; Izzet Celal Erdinler; Kadir Gurkan
Journal:  North Clin Istanb       Date:  2018-08-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.